Literature DB >> 12700401

Neonatal ontogeny of murine arylamine N-acetyltransferases: implications for arylamine genotoxicity.

Charlene A McQueen1, Binh Chau.   

Abstract

Age-related changes in the expression of xenobiotic biotransformation enzymes can result in differences in the rates of chemical activation and detoxification, affecting responses to the therapeutic and/or toxic effects of chemicals. Despite recognition that children and adults may exhibit differences in susceptibility to chemicals, information about when in development specific biotransformation enzymes are expressed is incomplete. N-acetyltransferases (NATs) are phase II enzymes that catalyze the acetylation of arylamine and hydrazine carcinogens and therapeutic drugs. The postnatal expression of NAT1 and NAT2 was investigated in C57Bl/6 mice. Hepatic NAT1 and NAT2 messenger RNAs (mRNAs) increased with age from neonatal day (ND) 4 to adult in a nonlinear fashion. The presence of functional proteins was confirmed by measuring NAT activities with the isoform selective substrates p-aminobenzoic acid and isoniazid, as well as the carcinogens 2-aminofluorene and 4-aminobiphenyl (4ABP). Neonatal liver was able to acetylate all of the substrates, with activities increasing with age. Protein expression of CYP1A2, another enzyme involved in the biotransformation of arylamines, showed a similar pattern. The genotoxicity of 4ABP was assessed by determining hepatic 4ABP-DNA adducts. There was an age-dependent increase in 4ABP-DNA adducts during the neonatal period. Thus, developmental increases in expression of NAT1 and NAT2 genes in neonates are associated with less 4ABP genotoxicity. The age-related pattern of expression of biotransformation enzymes in mice is consistent with human data for NATs and suggests that this may play a role in developmental differences in arylamine toxicity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12700401     DOI: 10.1093/toxsci/kfg086

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  9 in total

1.  Association of NAT2 genetic polymorphism with the efficacy of Neurotropin® for the enhancement of aggrecan gene expression in nucleus pulposus cells: a pilot study.

Authors:  Tomoko Nakai; Daisuke Sakai; Yoshihiko Nakamura; Natsumi Horikita; Erika Matsushita; Mitsuru Naiki; Masahiko Watanabe
Journal:  BMC Med Genomics       Date:  2021-03-11       Impact factor: 3.063

2.  Remdesivir and GS-441524 Extraction by Ex Vivo Extracorporeal Life Support Circuits.

Authors:  Carina E Imburgia; Joseph E Rower; Danielle J Green; Autumn M Mcknite; Walter E Kelley; Christopher A Reilly; Kevin M Watt
Journal:  ASAIO J       Date:  2021-11-17       Impact factor: 3.826

3.  Acetylator Genotype-Dependent Dyslipidemia in Rats Congenic for N-Acetyltransferase 2.

Authors:  Kyung U Hong; Mark A Doll; Angeliki Lykoudi; Raúl A Salazar-González; Mariam R Habil; Kennedy M Walls; Alaa F Bakr; Smita S Ghare; Shirish S Barve; Gavin E Arteel; David W Hein
Journal:  Toxicol Rep       Date:  2020-09-28

4.  Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues.

Authors:  Anwar Husain; Xiaoyan Zhang; Mark A Doll; J Christopher States; David F Barker; David W Hein
Journal:  Drug Metab Dispos       Date:  2007-02-07       Impact factor: 3.922

5.  Functional analysis of the human N-acetyltransferase 1 major promoter: quantitation of tissue expression and identification of critical sequence elements.

Authors:  Anwar Husain; Xiaoyan Zhang; Mark A Doll; J Christopher States; David F Barker; David W Hein
Journal:  Drug Metab Dispos       Date:  2007-06-25       Impact factor: 3.922

6.  Quantitative tissue and gene-specific differences and developmental changes in Nat1, Nat2, and Nat3 mRNA expression in the rat.

Authors:  David F Barker; Jason M Walraven; Elizabeth H Ristagno; Mark A Doll; J Christopher States; David W Hein
Journal:  Drug Metab Dispos       Date:  2008-09-17       Impact factor: 3.922

7.  A framework and case studies for evaluation of enzyme ontogeny in children's health risk evaluation.

Authors:  Gary Ginsberg; Suryanarayana V Vulimiri; Yu-Sheng Lin; Jayaram Kancherla; Brenda Foos; Babasaheb Sonawane
Journal:  J Toxicol Environ Health A       Date:  2017-09-11

8.  Structure and transcriptional regulation of the Nat2 gene encoding for the drug-metabolizing enzyme arylamine N-acetyltransferase type 2 in mice.

Authors:  Sotiria Boukouvala; Naomi Price; Kathryn E Plant; Edith Sim
Journal:  Biochem J       Date:  2003-11-01       Impact factor: 3.857

9.  Bioactivation of the human carcinogen aristolochic acid.

Authors:  Viktoriya S Sidorenko; Sivaprasad Attaluri; Irina Zaitseva; Charles R Iden; Kathleen G Dickman; Francis Johnson; Arthur P Grollman
Journal:  Carcinogenesis       Date:  2014-04-17       Impact factor: 4.944

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.